Autoimmune neuromuscular junction disorders are rare. However, myasthenia gravis is
being increasingly recognised in people older than 50 years. In the past 5–10 years …

Objective Myasthenia gravis (MG) people experience adverse psychiatric outcomes, which
may impact on their life and disturb their daily activity. Depression and anxiety are identified …

Myasthenia Gravis (MG) is an autoimmune disease with several comorbidities, however
information on MG mortality remains sparse. We conducted a nationwide register-based …

Background: Life-threatening myasthenic crisis (MC) occurs in 10–20% of the patients with
myasthenia gravis (MG). It is important to identify the predictors of progression to MC and …

Myasthenia gravis (MG) is a B-cell-mediated autoimmune disease and the most frequent
disorder of the neuromuscular junction. Characteristic symptoms are muscle weakness …

C5 that intercepts the formation of membranolytic attack complex that is fixed at the end-
plate by anti-AChR antibodies. Eculizumab is the first drug to be approved for refractory MG …

Background: There are limited studies on the comorbidities of myasthenic crisis (MC)
associated with age and gender, specifically from Indonesia. These data might be valuable …

Objectives: Neuromuscular disorders could have respiratory involvement early or late into
illness. Rarely, patients may present with a hypercapnic respiratory failure (with minimal …

The study was performed to evaluate the impact of cardiological disorders on the outcome of
myasthenic crisis (MC) requiring ventilation. The study includes 90 cases admitted to the …